{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:31:35Z","timestamp":1793273495642,"version":"4.5.0"},"reference-count":73,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"DOI":"10.1080\/14737140.2026.2746616","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:42:30Z","timestamp":1791452550000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Myelodysplastic syndromes\/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity"],"prefix":"10.1080","author":[{"given":"Shehab F.","family":"Mohamed","sequence":"first","affiliation":[{"name":"Hamad Medical Corporation (HMC)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation (HMC)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation (HMC)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Mesilhy","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation (HMC)","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,29]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-492884"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000063507"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2081-4"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149630"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01819-x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01299.x"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06421-y"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04608-7"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.297"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13902"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081462"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14149"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22602"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2004.12.019"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw024"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06776.x"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.005"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"e_1_3_5_24_1","doi-asserted-by":"crossref","unstructured":"Malcovati L Della Porta MG Strupp C et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433\u20131440. doi: 10.3324\/haematol.2011.044602","DOI":"10.3324\/haematol.2011.044602"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08893.x"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06374-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404385"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170553"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0245-2"},{"issue":"2","key":"e_1_3_5_30_1","first-page":"81","article-title":"Platelet response during the second cycle of decitabine treatment predicts survival in myelodysplastic syndrome patients","volume":"50","author":"Jung HA","year":"2015","unstructured":"Jung HA, Maeng CH, Kim M, et al. Platelet response during the second cycle of decitabine treatment predicts survival in myelodysplastic syndrome patients. Blood Res. 2015;50(2):81\u201387.","journal-title":"Blood Res"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4259"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13008"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610519"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017735"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71861"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/98.5.502"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167567"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000064703"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272559"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(93)90038-M"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1286-0"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.02.008"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12710"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17675"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01742-8"},{"issue":"3","key":"e_1_3_5_46_1","first-page":"92","article-title":"Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with isolated del(20q)","volume":"206","author":"Kanagal-Shamanna R","year":"2013","unstructured":"Kanagal-Shamanna R, Yin CC, Zuo Z, et al. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with isolated del(20q). Cancer Genet. 2013;206(3):92\u2013100.","journal-title":"Cancer Genet"},{"issue":"7","key":"e_1_3_5_47_1","first-page":"968","article-title":"Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies","volume":"28","author":"Yin CC","year":"2015","unstructured":"Yin CC, Medeiros LJ, Bueso-Ramos CE, et al. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol. 2015;28(7):968\u2013973.","journal-title":"Mod Pathol"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092596"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0104"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14423"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1734"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1382-0"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274753"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28663"},{"issue":"3","key":"e_1_3_5_55_1","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukemia progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomized double-blind trial","volume":"5","author":"Kantarjian H","year":"2018","unstructured":"Kantarjian H, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukemia progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomized double-blind trial. Lancet Haematol. 2018;5(3):e117\u2013e126.","journal-title":"Lancet Haematol"},{"key":"e_1_3_5_56_1","first-page":"2188","article-title":"Biomarker-guided romiplostim treatment in patients with lower-risk myelodysplastic syndromes and thrombocytopenia: results of the Europe trial","volume":"36","author":"Kubasch AS","year":"2022","unstructured":"Kubasch AS, Platzbecker U, Fenaux P, et al. Biomarker-guided romiplostim treatment in patients with lower-risk myelodysplastic syndromes and thrombocytopenia: results of the Europe trial. Leukemia. 2022;36:2188\u20132197.","journal-title":"Leukemia"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.713477"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.7999"},{"issue":"17","key":"e_1_3_5_59_1","first-page":"2054","article-title":"A randomized, double-blind study of romiplostim in patients with low- or intermediate-1-risk myelodysplastic syndrome receiving lenalidomide","volume":"30","author":"Wang ES","year":"2012","unstructured":"Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind study of romiplostim in patients with low- or intermediate-1-risk myelodysplastic syndrome receiving lenalidomide. J Clin Oncol. 2012;30(17):2054\u20132060.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00149-0"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30012-1"},{"key":"e_1_3_5_62_1","first-page":"1112","article-title":"Long-term efficacy and safety of eltrombopag in patients with low-risk myelodysplastic syndromes and severe thrombocytopenia: final results from the EQOL-MDS study","volume":"37","author":"Oliva EN","year":"2023","unstructured":"Oliva EN, Santini V, Poloni A, et al. Long-term efficacy and safety of eltrombopag in patients with low-risk myelodysplastic syndromes and severe thrombocytopenia: final results from the EQOL-MDS study. Leukemia. 2023;37:1112\u20131120.","journal-title":"Leukemia"},{"key":"e_1_3_5_63_1","first-page":"374","article-title":"Eltrombopag for advanced myelodysplastic syndromes and acute myeloid leukemia with severe thrombocytopenia: phase 1\/2 trial results","volume":"126","author":"Platzbecker U","year":"2015","unstructured":"Platzbecker U, Germing U, G\u00f6tze KS, et al. Eltrombopag for advanced myelodysplastic syndromes and acute myeloid leukemia with severe thrombocytopenia: phase 1\/2 trial results. Blood. 2015;126:374\u2013382.","journal-title":"Blood"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30228-4"},{"issue":"4","key":"e_1_3_5_65_1","first-page":"589","article-title":"Eltrombopag in combination with azacitidine in higher-risk myelodysplastic syndromes: results of a pilot phase I study","volume":"166","author":"Svensson T","year":"2014","unstructured":"Svensson T, Chow KU, H\u00f6glund M, et al. Eltrombopag in combination with azacitidine in higher-risk myelodysplastic syndromes: results of a pilot phase I study. Br J Haematol. 2014;166(4):589\u2013598.","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_3_5_66_1","first-page":"e34","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk myelodysplastic syndromes with thrombocytopenia (support): a randomized, double-blind, placebo-controlled phase 3 study","volume":"5","author":"Dickinson M","year":"2018","unstructured":"Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk myelodysplastic syndromes with thrombocytopenia (support): a randomized, double-blind, placebo-controlled phase 3 study. Lancet Haematol. 2018;5(1):e34\u2013e43.","journal-title":"Lancet Haematol"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.08.001"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02619"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14049"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.06.003"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000821"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-663237"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-667063"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01724-5"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.249995"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2746616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2746616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2746616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:31:27Z","timestamp":1793269887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2746616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,29]]},"references-count":73,"alternative-id":["10.1080\/14737140.2026.2746616"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2746616","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}